Case series on high grade appendiceal cancer with peritoneal and liver carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
| Autor: | Roy SP; General Surgery, John Hunter Hospital, University of Newcastle, Newcastle, Australia; Liver and Peritonectomy Unit, St George Hospital, Kogarah, Australia. Electronic address: susmitprosunroy@gmail.com., Al Zhahrani N; Liver and Peritonectomy Unit, St George Hospital, Kogarah, Australia; College of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. Electronic address: nayefalhariri@hotmail.com., Barat S; Southeast Sydney Local Health District, Australia; University of New South Wales, Australia. Electronic address: Shoma.Barat@health.nsw.gov.au., Morris DL; Liver and Peritonectomy Unit, St George Hospital, Kogarah, Australia; University of New South Wales, Australia; Liver and Peritonectomy Unit, St George Hospital, Kogarah, Australia; UNSW, St George and Sutherland Clinical School, NSW 2052, Australia; St George and Sutherland Clinical School, Kogarah, NSW 2217, Australia. Electronic address: david.morris@unsw.edu.au. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International journal of surgery case reports [Int J Surg Case Rep] 2022 May; Vol. 94, pp. 107027. Date of Electronic Publication: 2022 Apr 04. |
| DOI: | 10.1016/j.ijscr.2022.107027 |
| Abstrakt: | Background: Pseudomyxoma Peritonei (PMP) is a mucin producing cancer with appendix as primary site. Cytoreductive Surgery (CRS) combined with hyper-thermic intraperitoneal chemotherapy (HIPEC) is an established form of therapy known to prolong survival in patients with PMP and peritoneal carcinomatosis. Methods/patients In our case series, we present five cases of PMP with synchronous liver and peritoneal metastasis treated with CRS and HIPEC. It is a very rare condition which needs more research to be able to comment on overall survival. Results: However, in our study, we found lower age, female gender and complete cytoreduction in surgery to be favourable predictors for improved morbidity. Conclusion: In our experience, CRS/HIPEC seem to be feasible for patients with PMP with synchronous liver and peritoneal metastasis. (Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|